Literature DB >> 19860844

Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: a potent prognostic factor.

Daisuke Takeyama1, Yasuhiro Miki, Fumiyoshi Fujishima, Takashi Suzuki, Jun-Ichi Akahira, Shuko Hata, Go Miyata, Susumu Satomi, Hironobu Sasano.   

Abstract

Steroid and xenobiotic receptor (SXR) is a nuclear receptor activated by diverse exogenous and endogenous compounds and has been demonstrated to play a pivotal role in detoxification through its regulation of various metabolizing enzymes and transporters. Recent studies also demonstrated the potential roles of SXR in the regulation of apoptosis and inflammation in various carcinoma cells, but the status of SXR in human esophageal squamous cell carcinoma (ESCC) has not been examined. Therefore, in this study, we performed immunohistochemical and quantitative RT-PCR evaluations in human ESCC in order to clarify its biological and clinical significance. We first immunolocalized SXR in 73 human ESCC cases. SXR immunoreactivity was detected in the nuclei, or in both nuclei and cytoplasm of carcinoma cells (98%, 20% of cases, respectively). The status of nuclear SXR immunoreactivity was inversely correlated with histological grade, lymph node status, ki67/MIB1 labeling index, and positively correlated with retinoid X receptor alpha status. In addition, high nuclear SXR expression was significantly correlated with favorable clinical outcome of the patients. Multivariate analysis further demonstrated SXR status in carcinoma cells as an independent favorable prognostic factor of the patients. Results of quantitative RT-PCR study demonstrated that SXR mRNA expression was detected in three of five cases, and was marked higher in the cancerous tissue than non-neoplastic tissue of these patients. This is the first study to demonstrate the status of SXR in human ESCC and the results suggest that SXR is a potent favorable prognostic factor of human ESCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860844     DOI: 10.1111/j.1349-7006.2009.01380.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Nuclear localization signal region in nuclear receptor PXR governs the receptor association with mitotic chromatin.

Authors:  Manjul Rana; Amit K Dash; Kalaiarasan Ponnusamy; Rakesh K Tyagi
Journal:  Chromosome Res       Date:  2018-07-15       Impact factor: 5.239

Review 2.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

Authors:  Satyanarayana R Pondugula; Sridhar Mani
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

3.  Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma.

Authors:  Tasmin Reuter; Rolf Warta; Dirk Theile; Andreas D Meid; Juan Pablo Rigalli; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Gerhard Dyckhoff; Walter Emil Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-04       Impact factor: 3.000

4.  Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.

Authors:  Hongwei Wang; Madhukumar Venkatesh; Hao Li; Regina Goetz; Subhajit Mukherjee; Arunima Biswas; Liang Zhu; Andreas Kaubisch; Lei Wang; James Pullman; Kathleen Whitney; Makoto Kuro-o; Andres I Roig; Jerry W Shay; Moosa Mohammadi; Sridhar Mani
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

5.  Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders.

Authors:  Nagendra Kumar Chaturvedi; Sanjay Kumar; Seema Negi; Rakesh K Tyagi
Journal:  Mol Cell Biochem       Date:  2010-09-10       Impact factor: 3.396

6.  Expression of the PXR gene in various types of cancer and drug resistance.

Authors:  Enqi Qiao; Minghua Ji; Jianzhong Wu; Rong Ma; Xiaohua Zhang; Yuejun He; Quanbin Zha; Xue Song; Li-Wei Zhu; Jinhai Tang
Journal:  Oncol Lett       Date:  2013-01-22       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.